Altamira Therapeutics: Positive Phase 2 Results Published in Peer-Reviewed Journal
Swiss biotech, Altamira Therapeutics (Nasdaq: CYTO) has announced the publication of positive results from its Phase 2 clinical trial in the leading peer-reviewed journals in scientific and clinical inner ear research, Otology & Neurotology.
Altamira’s study demonstrated proof of concept and tolerability of AM-125 (intranasal betahistine) in surgery-induced acute vestibular syndrome (AVS).
The company’s share price rose more than 20% following the news.
Highlights
Altamira’s randomized, double-blind, placebo-controlled TRAVERS trial enrolled a total of 124 patients, at more than 10 study sites across Europe.
Enrolled patients were suffering from AVS following surgery for the removal of a tumor. AVS is characterized by the sudden onset of continuous vertigo, nausea, head motion intolerance, and unstable balance.
The TRAVERS trial demonstrated good tolerability of AM-125 and a dose- and time-dependent improvement in balance, and signs and symptoms of vestibular dysfunction.
Altamira says the trial suggests that AM-125 helps to accelerate vestibular compensation and enables patients to regain balance and recover faster.
The company expects to submit an Investigational New Drug (IND) application for AM-125 to the FDA next month.
About Altamira Therapeutics
Altamira Therapeutics (Nasdaq:CYTO) is developing RNA-based therapeutics for extrahepatic targets using its OligoPhore™ and SemaPhore™ delivery platforms. The Company has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. In addition, Altamira is in the process of divesting and/or out-licensing its legacy assets in allergology and viral infection (Bentrio® OTC nasal spray; commercial) and inner ear therapeutics (AM-125 nasal spray for vertigo; post Phase 2; Keyzilen® and Sonsuvi® for tinnitus and hearing loss; Phase 3). Altamira’s main operations are in Basel, Switzerland.
